Our latest news

Seda’s Jake Dickinson Shortlisted as Bionow Promising Technologist of the Year 2020

CellCentric’s first-in-class p300/CBP inhibitor CCS1477 publishes in Cancer Discovery

Paul Dickinson Presents: Developing Clinically Relevant Dissolution Specifications in APS Virtual Webinar Series

Publication of Influential Workshop Output on Physiologically Based Biopharmaceutics Modeling (PBBM)

Bionow Oncology Conference: Pharmaceutical Development Session featuring Paul Stott and Claire Patterson

New Appointments at Seda

Enhancing our Analytical Capability